参芪扶正注射液对慢性心功能不全患者免疫功能及血粘度的影响

目的:研究参芪扶正注射液对慢性心功能不全患者体液免疫(IgG、IgA、IgM),细胞免疫(T细胞亚群)及超氧化物歧化酶(SOD)、过氧化脂质(LPO)及血粘度的影响.方法:将60例属NYHA心功能级为2～4级的住院患者随机分成两组,在西医常规治疗的同时,治疗组加用参芪扶正注射液250 ml静滴,每天一次,对照组用硝酸甘油10 mg加入5%葡萄糖注射液500 ml静脉滴注,每天一次,疗程均为20天.两组治疗前后均采血测定IgG、IgA、IgM、T细胞亚群、SOD、LPO和血粘度,并进行临床疗效评价.结果:治疗组的临床心功能改善显效率及总有效率明显优于对照组(P＜0.05),两组治疗后的左室射血分数(LVEF)和收缩末期容积(ESV)较治疗前均有明显改善(P＜0.05,P＜0.01),且治疗组优于对照组(P＜0.05).治疗组治疗后的CD4、CD4/CD8、SOD的值明显上升(P＜0.05),IgG、IgA、IgM、LPO明显下降(P＜0.05);对照组各项指标无明显变化(P＞0.05).两组治疗后治疗组的血粘度较治疗前有显著性差异(P＜0.05),与对照组比较差异也具显著性(P＜0.05).结论:参芪扶正注射液能够改善患者的免疫功能,对治疗有一定的作用.

Effect of Shenqi Fuzheng Injection(SFI) on Immune Function in Patients with Congestive Heart Failure

OBJECTIVE: To study the effect of Shenqi Fuzheng injection on the humoral immunity (IgG IgM IgA), cellular immunity (T-lymphocyte subsets), Superoxide dismutase (SOD). Lpo and Plasma viscosity in the patients with congestive heart failure (CHF). METHODS: Sixty patients with CHF, whose heart function belonged to NYHA grade II-IV were randomly divide into two groups. The treaded group were treated with SFI 100 ml, and the control group were treated by nitroglycerine in jection 10 mg, the drug were administered respectively by adding in 5% glucose solution 500 ml for intravenous dripping, once a day, 20 days as one therapeutic course. Venous blood from cubital vein was collected before and after treatment to detect the IgG, IgM, IgA, T-lymphocyte subsets, SOD, LPO and Plasma viscosity. RESULTS: The clinical heart function markedly improved rate and total effective rate in the treated group was singificantly better than those in the control group respectively (P < 0.05). the left ventricular ejecting frection (LVEF) and end syctolic volume (ESV) were improved in both group (P < 0.05, P < 0.01), and the improvement in the treated group was superior to that in the control group (P < 0.05). In the treated group after treatment, the CD4, SOD level and CD4/DC8 ratio increased (P < 0.05), level of LPO, IgG and IgM lowered (P < 0.05) significantly, while those in the control group were not changed singificantly (P > 0.05). Plasma viscosity of treatment group also got better improved than before (P < 0.05), and there was a significantly difference between the two groups after treatment (P < 0.05). CONCLUSION: SFI Can improve the immune funtion of CHF patients, and can be taken as an importmant auxiliary treatment for CHF.